Saeed Rafii, MD, PhD

home / authors / saeed-rafii-md-phd

Articles

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

Saeed Rafii, MD, PhD
September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Read More

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

Saeed Rafii, MD, PhD
June 14th 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

Read More

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

Saeed Rafii, MD, PhD
December 11th 2015

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).

Read More

Dr. Rafii Discusses Clinical Outcomes With Olaparib in Patients with Ovarian Cancer

Dr. Rafii Discusses Clinical Outcomes With Olaparib in Patients with Ovarian Cancer

Saeed Rafii, MD, PhD
June 16th 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need